Cadila's stock ended the day 5.85 per cent higher at Rs 903.15 on the BSE. During the day, the scrip rose by 7.35 per cent to Rs 915.95. At the NSE, the drug firm's stock zoomed 5.46 per cent to close at Rs 901.45.
Cadila today reported 81.54 per cent increase in consolidated net profit at Rs 185.97 crore for the third quarter ended December 31, 2013. It had reported net profit of Rs 102.44 crore in October-December quarter last year.
Net sales were up at Rs 1,838.04 crore as against Rs 1,561.02 crore in the year-ago period, the company said in a BSE filing. Overall expenses in the third quarter were at Rs 1,626 crore, compared to Rs 1,402.94 crore in the same quarter of last fiscal.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%